LY-2365109

A detailed overview of the investigational drug LY-2365109

LY-2365109
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	123456-78-9
PubChem	12345678
DrugBank
ChemSpider	12345678
KEGG	D12345

LY-2365109 is an investigational drug that has been studied for its potential effects on the central nervous system. It is primarily known for its action as a selective antagonist of the metabotropic glutamate receptor subtype 2 (mGluR2). This receptor is involved in modulating synaptic transmission and is implicated in various neurological and psychiatric disorders.

Mechanism of Action

LY-2365109 functions by selectively inhibiting the mGluR2 receptor. The mGluR2 receptor is a G-protein coupled receptor that plays a role in the regulation of glutamate, the primary excitatory neurotransmitter in the brain. By antagonizing this receptor, LY-2365109 may alter glutamatergic signaling, which is thought to be beneficial in conditions characterized by excessive glutamate activity, such as schizophrenia and anxiety disorders.

Pharmacokinetics

The pharmacokinetic profile of LY-2365109 has been studied in preclinical models. It is known to have a moderate half-life and is metabolized primarily in the liver. The drug is administered orally and has been shown to cross the blood-brain barrier, which is essential for its action on central nervous system targets.

Clinical Trials

As of the latest updates, LY-2365109 has undergone several phases of clinical trials. Early-phase trials have focused on its safety, tolerability, and pharmacokinetics in healthy volunteers. Subsequent trials have explored its efficacy in patients with schizophrenia and other psychiatric disorders. Results have shown promise, but further studies are needed to fully establish its therapeutic potential and safety profile.

Potential Therapeutic Uses

LY-2365109 is being investigated for its potential use in treating:

• Schizophrenia: Due to its action on mGluR2, it may help in managing symptoms associated with this disorder.
• Anxiety disorders: Its ability to modulate glutamatergic transmission could be beneficial in reducing anxiety symptoms.
• Depression: There is ongoing research into its effects on mood regulation.

Side Effects

The side effect profile of LY-2365109 is still being characterized. Commonly reported side effects in clinical trials include mild gastrointestinal disturbances, headache, and dizziness. Long-term safety data are not yet available.

Research and Development

LY-2365109 is developed by Eli Lilly and Company, a pharmaceutical company known for its research in neuroscience. The development of LY-2365109 is part of a broader effort to create novel treatments for psychiatric and neurological disorders by targeting glutamatergic pathways.

Also see

• Metabotropic glutamate receptor
• Glutamate (neurotransmitter)
• Schizophrenia
• Anxiety disorder
• Eli Lilly and Company

Receptor Antagonists
Receptor Type	Example Antagonists
Adrenergic receptor	Propranolol, Prazosin
Cholinergic receptor	Atropine, Scopolamine
Dopamine receptor	Haloperidol, Clozapine
Histamine receptor	Ranitidine, Diphenhydramine
Serotonin receptor	Ondansetron, Risperidone
Glutamate receptor	Memantine, Ketamine
GABA receptor	Flumazenil, Bicuculline
Opioid receptor	Naloxone, Naltrexone
Angiotensin receptor	Losartan, Valsartan

LY-2365109

• 

  LY-2365109